A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS USE OF FORWARD-LOOKING STATEMENTS IN THIS REPORT This annual report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”) contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this Annual Report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. These forward-looking statements include, but are not limited to, predictions regarding: our business plan; the commercial viability of our technology and products incorporating our technology; the effects of competitive factors on our technology and products incorporating our technology; expenses we will incur in operating our business; our liquidity and sufficiency of existing cash; the success of our financing plans; and the outcome of pending or threatened litigation.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 7.8M | 7.8M | 18M | 12M | 5.9M | - |
| Net Income | -12M | -12M | -2.4M | -3.5M | -4.5M | -7.1M |
| EPS | $-0.04 | $-0.04 | $-0.01 | $-0.01 | $-0.02 | $-0.03 |
| Free Cash Flow | -8.3M | -8.3M | -4.4M | -2.8M | -3.0M | -4.0M |
| ROIC | -333.6% | -141.2% | -90.5% | -294.2% | -178.7% | -134.2% |
| Gross Margin | 43.9% | 43.9% | 44.2% | 50.3% | 48.6% | - |
| Debt/Equity | 0.83 | 0.83 | 0.23 | 0.21 | 0.25 | 0.27 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -15M | -15M | -4.3M | -4.6M | -5.4M | -6.8M |
| Operating Margin | -191.3% | -191.3% | -24.4% | -37.4% | -91.6% | - |
| ROE | -291.4% | -182.7% | -27.1% | -51.2% | -91.7% | -152.2% |
| Shares Outstanding | 295M | 295M | 240M | 350M | 224M | 236M |
BIOLARGO, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 46.7%.
BIOLARGO, INC. (BLGO) has a 5-year average return on invested capital (ROIC) of -136.1%. This is below average and may indicate limited pricing power.
BIOLARGO, INC. (BLGO) has a market capitalization of $47M. It is classified as a small-cap stock.
BIOLARGO, INC. (BLGO) does not currently pay a regular dividend.
BIOLARGO, INC. (BLGO) operates in the Chemicals & Allied Products industry, within the Materials sector.
BIOLARGO, INC. (BLGO) reported annual revenue of $8 million in its most recent fiscal year, based on SEC EDGAR filings.
BIOLARGO, INC. (BLGO) has a net profit margin of -151.7%. The company is currently unprofitable.
BIOLARGO, INC. (BLGO) generated $-8 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
BIOLARGO, INC. (BLGO) has a debt-to-equity ratio of 0.83. This indicates moderate leverage.
BIOLARGO, INC. (BLGO) reported earnings per share (EPS) of $-0.04 in its most recent fiscal year.
BIOLARGO, INC. (BLGO) has a return on equity (ROE) of -182.7%. A negative ROE may indicate losses or negative equity.
BIOLARGO, INC. (BLGO) has a 5-year average gross margin of 46.7%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for BIOLARGO, INC. (BLGO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BIOLARGO, INC. (BLGO) has a book value per share of $0.01, based on its most recent annual SEC filing.
No recent press releases.